Observing health outcomes in HIV patients with other health issues
Renal, Metabolic, Hepatic and Bone Outcomes in People Living With HIV and Other Co-morbidities Receiving Different Anti-retroviral Regimens
Chinese University of Hong Kong · NCT05824130
This study looks at how having other health issues affects the health of people living with HIV who are on treatment over the course of a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong (other) |
| Locations | 1 site (Shatin) |
| Trial ID | NCT05824130 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the health outcomes of people living with HIV (PLWH) who also have one or more co-morbidities while receiving anti-retroviral therapy (ART). Participants will be followed for one year to assess the prevalence and incidence of renal, metabolic, hepatic, and bone diseases. The study will take place at a co-morbidities clinic, where participants will undergo assessments at baseline and during follow-up visits. The focus is on understanding how these co-morbidities impact the health of PLWH over time.
Who should consider this trial
Good fit: Ideal candidates include HIV-positive individuals over 18 years old with one or more specified co-morbidities who are receiving certain ART regimens.
Not a fit: Patients who have recently been diagnosed with AIDS or have been hospitalized for acute medical problems within the last six months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into managing HIV patients with co-morbidities, potentially improving their overall health outcomes.
How similar studies have performed: Other studies have explored health outcomes in HIV patients with co-morbidities, indicating a growing interest in this area, though specific results may vary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. HIV antibody positive 2. Age above 18 years 3. Diagnosis of one or more co-morbidities, including hypertension, diabetes, dyslipidemia, chronic kidney disease, chronic liver disease, and cardiovascular diseases 4. Receiving ART regimen, which consists of B/F/TAF, or 1-2 NRTI(s), plus another anti-retroviral drug, including INSTI other than bictegravir, NNRTI, or protease inhibitor Exclusion Criteria: 1. Recent diagnosis of AIDS within 6 months 2. Recent hospitalization for management of acute medical problems within 6 months 3. Receiving ART regimens other than the combinations listed in Inclusion Criteria
Where this trial is running
Shatin
- Prince of Wales Hospital — Shatin, Hong Kong (RECRUITING)
Study contacts
- Principal investigator: Grace Lui — Chinese University of Hong Kong
- Study coordinator: Catherine Cheung, Mphil
- Email: catherinecheung@cuhk.edu.hk
- Phone: +852 35053376
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hiv